Mortality associated with lithium and valproate treatment of US Veterans Health Administration patients with mental disorders

British Journal of Psychiatry

Volumn 207, Issue 1, 2015, Pages 55-63

  Smith, Eric G ^a,b   Austin, Karen L ^a   Kim, Hyungjin Myra ^a,c   Eisen, Susan V ^a,d   Kilbourne, Amy M ^e,f   Miller, Donald R ^a   Zivin, Kara ^a,f   Hannemann, Claire ^a   Sauer, Brian C ^e,g   Valenstein, Marcia ^a,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d BOSTON UNIVERSITY   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; VALPROIC ACID; NEUROLEPTIC AGENT; TRANQUILIZER;

AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HOSPITAL ADMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH SERVICE; OVERALL SURVIVAL; PATIENT MONITORING; PREVALENCE; PROPENSITY SCORE; PSYCHOSOCIAL REHABILITATION; SEX DIFFERENCE; VERY ELDERLY; VETERANS HEALTH; COHORT ANALYSIS; MENTAL DISORDERS; MENTAL HEALTH; MORTALITY; REGRESSION ANALYSIS; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; LITHIUM; MALE; MENTAL DISORDERS; MENTAL HEALTH; REGRESSION ANALYSIS; RISK FACTORS; VALPROIC ACID; VETERANS HEALTH;

EID: 84937204261     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.113.138685     Document Type: Article

References (74)

1. Morton WA, Sonne SC, Lydiard RB. Lithium side effects in the medically ill. Int J Psychiatry Med 1993; 23: 357-82.
2. Frost RE, Messiha FS. Clinical uses of lithium salts. Brain Res Bull 1983; 11: 219-31.
3. Carmen J, Okafor K, Ike E. The effects of lithium therapy on leukocytes: a 1-year follow-up study. J Natl Med Assoc 1993; 85: 301-3.
4. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006; 3: A42.
5. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000; 48: 740-54.
6. Hicks D. Lithium induced renal toxicity-a review of the literature. S D J Med 1991; 44: 343-5.
7. Gitlin M. Lithium and the kidney: an updated review. Drug Saf 1999; 20: 231-43.
8. Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemol Ment Health 2006; 2: 23.
9. Weintraub M, Hes JP, Rotmensch HH, Soferman G, Liron M. Extreme sinus bradycardia associated with lithium therapy. Isr J Med Sci 1983; 19: 353-5.
10. Montalescot G, Levy Y, Hatt PY. Serious sinus node dysfunction caused by therapeutic doses of lithium. Int J Cardiol 1984; 5: 94-6.
11. Wolf ME, Ranade V, Molnar J, Somberg J, Mosnaim AD. Hypercalcemia, arrhythmia, and mood stabilizers. J Clin Psychopharmacol 2000; 20: 260-4.
12. Norton B, Whalley LJ. Mortality of a lithium-treated population. Br J Psychiatry 1984; 145: 277-82.
13. Coppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P, Hermon C. Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord 1991; 23: 1-7.
14. Vestergaard P, Aagaard J. Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord 1991; 21: 33-8.
15. Muller-Oerlinghausen B, Ahrens B, Grof E, Grof P, Lenz G, Schou M, et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand 1992; 86: 218-22.
16. Ahrens B, Muller-Oerlinghausen B, Schou M, Wolf T, Alda M, Grof E, et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord 1995; 33: 67-75.
17. Nilsson A. Mortality in recurrent mood disorders during periods on and off lithium. A complete population study in 362 patients. Pharmacopsychiatry 1995; 28: 8-13.
18. Brodersen A, Licht RW, Vestergaard P, Olesen AV, Mortensen PB. Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry 2000; 176: 429-33.
19. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68: 167-81.
20. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-19.
21. Kilbourne AM, Morden NE, Austin K, Ilgen M, McCarthy JF, Dalack G, et al. Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry 2009; 31: 555-63.
22. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11-53.
23. Miller BJ, Paschall CB, 3rd, Svendsen DP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv 2006; 57: 1482-7.
24. Zivin K, Ilgen MA, Pfeiffer PN, Welsh DE, McCarthy J, Valenstein M, et al. Early mortality and years of potential life lost among veterans affairs patients with depression. Psychiatr Serv 2012; 63: 823-6.
25. Young AH, Hammond JM. Lithium in mood disorders: increasing evidence base, declining use? Br J Psychiatry 2007; 191: 474-6.
26. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002; 159: 1005-10.
27. Wolfsperger M, Greil W, Rossler W, Grohmann R. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J Affect Disord 2007; 99: 9-17.
28. Shulman KI, Rochon P, Sykora K, Anderson G, Mamdani M, Bronskill S, et al. Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence. BMJ 2003; 326: 960-1.
29. Blow FC, Valenstein M, Austin K, Khanuja K, McCarthy JF. Specialty Care for Veterans with Depression in the VHA: 2002 National Depression Registry Report. VA National Serious Mental Illness Treatment Research & Evaluation Center (SMITREC), VHA Health Services Research & Development, 2003.
30. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
31. Hernan MA, Robins JM. Authors' response, part I: observational studies analyzed like randomized experiments: best of both worlds. Epidemiology 2008; 19: 789-92.
32. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011; 365: 1896-904.
33. Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol 2002; 12: 462-8.
34. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512-22.
35. Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303: 1401-9.
36. Wyss R, Girman CJ, Locasale RJ, Alan Brookhart M, Sturmer T. Variable selection for propensity score models when estimating treatment effects on multiple outcomes: a simulation study. Pharmacoepidemiol Drug Saf 2013; 22: 77-85.
37. Selim AJ, Berlowitz DR, Fincke G, Rosen AK, Ren XS, Christiansen CL, et al. Risk-adjusted mortality rates as a potential outcome indicator for outpatient quality assessments. Med Care 2002; 40: 237-45.
38. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006; 163: 1149-56.
39. Patrick AR, Schneeweiss S, Brookhart MA, Glynn RJ, Rothman KJ, Avorn J, et al. The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf 2011; 20: 551-9.
40. Pearl J. Invited commentary: understanding bias amplification. Am J Epidemiol 2011; 174: 1223-7.
41. Brooks JM, Ohsfeldt RL. Squeezing the balloon: propensity scores and unmeasured covariate balance. Health Serv Res 2013; 48: 1487-507.
42. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J 2009; 51: 171-84.
43. Faries DE, Leon AC, Haro JM, Obenchain RL, SAS Institute. Analysis of Observational Health Care Data using SAS. SAS Institute, 2010.
44. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007; 26: 734-53.
45. Muller-Oerlinghausen B, Wolf T, Ahrens B, Glaenz T, Schou M, Grof E, et al. Mortality of patients who dropped out from regular lithium prophylaxis: a collaborative study by the International Group for the Study of Lithium-treated patients (IGSLI). Acta Psychiatr Scand 1996; 94: 344-7.
46. Bocchetta A. Mortality follow-up of patients since commencing lithium therapy. J Clin Psychopharmacol 2005; 25: 197-9.
47. Christodoulou GN, Lykouras EP. Abrupt lithium discontinuation in manic-depressive patients. Acta Psychiatr Scand 1982; 65: 310-4.
48. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48: 1082-8.
49. Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993; 50: 448-55
50. Goodwin GM. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 1994; 164: 149-52.
51. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002; 63: 384-90.
52. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001; 52: 805-11.
53. Schumann C, Lenz G, Berghofer A, Muller-Oerlinghausen B. Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res 1999; 89: 247-57.
54. Maarbjerg K, Aagaard J, Vestergaard P. Adherence to lithium prophylaxis: I. Clinical predictors and patient's reasons for nonadherence. Pharmacopsychiatry 1988; 21: 121-5.
55. Aagaard J, Vestergaard P. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disord 1990; 18: 259-66.
56. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996; 153: 993-1000.
57. Kessing LV, Sondergard L, Kvist K, Andersen PK. Adherence to lithium in naturalistic settings: results from a nationwide pharmacoepidemiological study. Bipolar Disord 2007; 9: 730-6.
58. Lolich M, Vazquez GH, Alvarez LM, Tamayo JM. Psychosocial interventions in bipolar disorder: a review. Actas Esp Psiquiatr 2012; 40: 84-92.
59. Colom F, Vieta E, Sanchez-Moreno J, Palomino-Otiniano R, Reinares M, Goikolea JM, et al. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry 2009; 194: 260-5.
60. Kessing LV, Hansen HV, Hvenegaard A, Christensen EM, Dam H, Gluud C, et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry 2013; 202: 212-9.
61. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxf) 2009; 23: 346-88.
62. Chao SH, Urbano FL. Introduction: Medicare Section 1013 and AHRQ's Effective Health Care Program. J Manag Care Pharm 2007; 13 (suppl 1): S3-6.
63. Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007; 164: 1568-76.
64. Schneeweiss S, Patrick AR, Solomon DH, Mehta J, Dormuth C, Miller M, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry 2010; 67: 497-506.
65. Soyka M, Apelt SM, Lieb M, Wittchen HU. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 2006; 26: 657-60.
66. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353: 2335-41.
67. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012; 169: 71-9.
68. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8: 625-39.
69. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 1467-73.
70. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60 (suppl 2): 77-84.
71. Ray WA. Observational studies of drugs and mortality. N Engl J Med 2005; 353: 2319-21.
72. Manwani SG, Szilagyi KA, Zablotsky B, Hennen J, Griffin ML, Weiss RD. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. J Clin Psychiatry 2007; 68: 1172-6.
73. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385-95.
74. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011; 199: 57-63.